Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem

Department of Physiology and Neuroscience, New York University School of Medicine, New York, NY 10016, USA.
Journal of Neurochemistry (Impact Factor: 4.28). 06/2011; 118(4):658-67. DOI: 10.1111/j.1471-4159.2011.07337.x
Source: PubMed


Targeting hyperphosphorylated tau by immunotherapy is emerging as a promising approach to treat tauopathies such as Alzheimer's disease and frontotemporal dementia. We have previously reported that active tau immunization clears tau aggregates from the brain and attenuates or prevents functional impairments in two different tangle mouse models. Here, we assessed the efficacy of passive immunization with the PHF1 antibody, which targets a phospho-epitope within one of our active immunogens. Homozygous female tangle mice (JNPL3, 2-3 months) were injected intraperitoneally once per week with PHF1 or pooled mouse IgG (250 μg/125 μL; n = 10 per group) for a total of 13 injections. Their behavior was assessed at 5-6 months of age and brain tissue was subsequently harvested for analyses of treatment efficacy. The treated mice performed better than controls on the traverse beam task (p < 0.03), and had 58% less tau pathology in the dentate gyrus of the hippocampus (p = 0.02). As assessed by western blots, the antibody therapy reduced the levels of insoluble pathological tau by 14-27% (PHF1, p < 0.05; PHF1/total tau, p < 0.0001) and 34-45% (CP13 or CP13/total tau, p < 0.05). Levels of soluble tau and sarkosyl soluble tau were unchanged, compared with controls, as well as total tau levels in all the fractions. Plasma levels of PHF1 correlated inversely with tau pathology in the brainstem (p < 0.01), with a strong trend in the motor cortex (p < 0.06) as well as with insoluble total tau levels (p < 0.02), indicating that higher dose of antibodies may have a greater therapeutic effect. Significant correlation was also observed between performance on the traverse beam task and PHF1 immunoreactivity in the dentate gyrus (p < 0.05) as well as with insoluble PHF1/total tau ratio on western blots (p < 0.04). These results show that passive immunization with tau antibodies can decrease tau pathology and functional impairments in the JNPL3 model. Future studies will determine the feasibility of this approach with other monoclonals and in different tangle models in which thorough cognitive assessment can be performed.

3 Reads
  • Source
    • "However, there was no change in survival between mice injected with either PHF1 or MC1 from 6 to 14 months of age versus control Tg mice (d'Abramo et al., 2013). Previously, it had been shown that PHF1 is able to decrease tau-related pathology when treatment is started prior to the onset of disease (Boutajangout et al., 2011). Together, these results suggest that, although immunotherapy directed toward tau holds promise , there is some risk of toxicity. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is the most prevalent form of dementia worldwide and is an emerging global epidemic. It is characterized by an imbalance between production and clearance of amyloid β (Aβ) and tau proteins. Oligomeric forms of Aβ and tau are believed to be the most toxic. Dramatic results from AD animal models showed great promise for active and passive immune therapies targeting Aβ. However, there is very limited evidence in human studies of the clinical benefits from these approaches. Immunotherapies targeting only tau pathology have had some success but are limited so far to mouse models. The majority of current methods is based on immunological targeting of a self-protein; hence, benefits need to be balanced against risks of stimulating excessive autoimmune toxic inflammation. For greater efficacy the next generation of vaccines needs to focus more on concurrently targeting all the intermediate toxic conformers of oligomeric Aβ and tau species. Copyright © 2015 Elsevier Inc. All rights reserved.
    Neuron 03/2015; 85(6):1162-1176. DOI:10.1016/j.neuron.2014.12.064 · 15.05 Impact Factor
  • Source
    • "The authors found that the antibody MC1, which targets PHF-tau, was more efficacious, vs. the DA31 antibody, which targets normal tau, and suggest that the antibody target, and not its affinity, is most critical in determining its in vivo effectiveness [24]. In a separate study by Boutajangout et al., also utilizing a passive immunization approach, administration of the PHF1 antibody, which targets pathological tau, lead to better performance on the traverse beam task, and 58% less tau pathology in the hippocampus [25]. While Boutajangout et al., and others using immunotherapy against pathological tau, have shown positive results, the use of tau only transgenic models makes extrapolating the results to potential efficacy in human AD patients difficult. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is a proteinopathy characterized by the accumulation of β-amyloid (Aβ) and tau. To date, clinical trials indicate that Aβ immunotherapy does not improve cognition. Consequently, it is critical to modulate other aspects of AD pathology. As such, tau represents an excellent target, as its accumulation better correlates with cognitive impairment. To determine the effectiveness of targeting pathological tau, with Aβ pathology present, we administered a single injection of AT8, or control antibody, into the hippocampus of aged 3xTg-AD mice. Extensive data indicates that phosphorylated Ser202 and Thr205 sites of tau (corresponding to the AT8 epitope) represent a pathologically relevant target for AD. We report that immunization with AT8 reduced somatodendritic tau load, p-tau immunoreactivity, and silver stained positive neurons, without affecting Aβ pathology. We also discovered that tau pathology soon reemerges post-injection, possibly due to persistent Aβ pathology. These studies provide evidence that targeting p-tau may represent an effective treatment strategy: potentially in conjunction with Aβ immunotherapy.
    Neuroscience Letters 07/2014; 575:96–100. DOI:10.1016/j.neulet.2014.05.047 · 2.03 Impact Factor
  • Source
    • "For example, multiple Ab antibodies were shown to reduce Ab burden in preclinical models and several of them have progressed to clinical trials for treating AD patients (Lemere and Masliah, 2010). Immunotherapies against intracellular proteins such as tau (Boutajangout et al., 2011; d&apos;Abramo et al., 2013; Yanamandra et al., 2013), SOD1 (Gros-Louis et al., 2010), Huntingtin (Wolfgang et al., 2005), and a-syn (Bae et al., 2012; Masliah et al., 2005, 2011) also have been explored in transgenic (Tg) mouse models and shown to decrease protein aggregation and neurodegeneration. However , only one study demonstrated a mechanism of action where antibody treatment reduced ''seeding'' activity of tau fibrils (Yanamandra et al., 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Accumulation of misfolded alpha-synuclein (α-syn) into Lewy bodies (LBs) and Lewy neurites (LNs) is a major hallmark of Parkinson's disease (PD) and dementia with LBs (DLB). Recent studies showed that synthetic preformed fibrils (pffs) recruit endogenous α-syn and induce LB/LN pathology in vitro and in vivo, thereby implicating propagation and cell-to-cell transmission of pathological α-syn as mechanisms for the progressive spread of LBs/LNs. Here, we demonstrate that α-syn monoclonal antibodies (mAbs) reduce α-syn pff-induced LB/LN formation and rescue synapse/neuron loss in primary neuronal cultures by preventing both pff uptake and subsequent cell-to-cell transmission of pathology. Moreover, intraperitoneal (i.p.) administration of mAb specific for misfolded α-syn into nontransgenic mice injected intrastriatally with α-syn pffs reduces LB/LN pathology, ameliorates substantia nigra dopaminergic neuron loss, and improves motor impairments. We conclude that α-syn antibodies could exert therapeutic effects in PD/DLB by blocking entry of pathological α-syn and/or its propagation in neurons.
    Cell Reports 06/2014; 7(6). DOI:10.1016/j.celrep.2014.05.033 · 8.36 Impact Factor
Show more


3 Reads